Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 274 No 7334 p109
29 January 2005

This article
Reprint   Photocopy

PDF 120K, Acrobat Reader

Letters

· Controlled drugs
· Diamorphine shortage (2)
· Medicines information
· Placebo effect
· The Society (16)
· Registration examination (2)
· Dispensing
· We've had enough of...


Letters to the Editor

Medicines information

Error database clarification

From J. M. Horwood, MRPharmS, and others

We would like to clarify the recent news item about the establishment of a medicines information error database (PJ, 15 January, p42). As written, the piece could suggest that this database is duplicating work already being undertaken by the National Patient Safety Association and other recognised schemes. We would like to reassure readers that this is not the case and explain its purpose.

The database referred to has been set up by the Clinical Governance Working Group of UK Medicines Information (UKMi) to capture data on incidents (errors and near misses) occurring within the practice of MI services in NHS hospital pharmacy departments across the UK. It has been named IRMIS (Incident Reporting in Medicines Information Scheme) to reflect this. It has not been set up to record medication errors and near misses occurring during prescribing, administration etc, because there are existing systems to capture these data.

The database is secured on the NHSnet and is accessed via individual user names and passwords. It is available to all hospital MI services in the UK and all data are anonymous.

Any incidents occurring with MI practice should be reported via hospital trust reporting systems in the same way as dispensing errors, but should also be reported via IRMIS. By collecting data about incidents within our own practice in a central database, we will be able to determine trends and share learning. This will help to reduce the likelihood of similar incidents occurring in the practice of other MI services and inform training programmes, risk management strategies and national standards accordingly.

The NPSA is aware of the scheme and we will ensure our learning is fed into the work of the agency so that it is shared more widely.

Julia Horwood
Elena Grant
Fiona Woods

Clinical Governance Working Groups
UKMi

Send your letter to The Editor

Previous Topic (Diamorphine shortage)
Next Topic (Placebo effect)

Back to Top


©The Pharmaceutical Journal